Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ImClone, sanofi settle Erbitux patent case

IMCL and sanofi-aventis (Euronext:SAN; SNY) settled patent litigation related to Erbitux cetuximab with Yeda Research and Development (Rehovot, Israel), the licensing arm of the Weizmann Institute. The settlement acknowledges

Read the full 292 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE